Dolutegravir 50 mg    (DrugBank: Dolutegravir)

1 disease
告示番号疾患名(ページ内リンク)臨床試験数
265脂肪萎縮症1

265. 脂肪萎縮症 [臨床試験数:109,薬物数:164(DrugBank:59),標的遺伝子数:26,標的パスウェイ数:94
Searched query = "Lipodystrophy", "Berardinelli-Seip syndrome", "Lawrence syndrome", "Barraquer-Simons syndrome"
The queries were searched in Public_title, Scientific_title, and Condition. Export date: 03/15/2021. Trials are sorted by Date_enrollment from most recent to oldest in the table.
1 / 109 trial found
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1NCT04340388
(ClinicalTrials.gov)
June 20201/4/2020Contribution of Dolutegravir to Obesity and Cardiovascular DiseaseContribution of the Integrase Inhibitor Dolutegravir to Obesity and Cardiovascular Disease in Persons Living With HIVHIV-1-infection;Antiviral Drug Adverse Reaction;Vascular Diseases;Cardiovascular Abnormalities;Abnormality of Adipose Tissue;Body Weight Changes;Body Fat Disorder;HIV-Associated Lipodystrophy SyndromeDrug: Dolutegravir 50 MG;Drug: Antiretroviral/Anti HIVAugusta UniversityNULLNot yet recruiting18 Years100 YearsAll30Phase 4NULL